SCHEMBL4144286

SCHEMBL4144286

Cc1cccc(Oc2ccc3c(C)n[nH]c3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.49
KDR P35968 9/20 0.47
CHEK1 O14757 6/20 0.47
FGFR1 P11362 3/20 0.47
HSD17B10 Q99714 2/20 0.45
CDK4 P11802 2/20 0.44
CCND1 P24385 2/20 0.44
CCND3 P30281 2/20 0.44
LCK P06239 1/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
LYN P07948 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 1/20 0.43
TTBK1 Q5TCY1 1/20 0.41
TTBK2 Q6IQ55 1/20 0.41
ACHE P22303 1/20 0.41
AR P10275 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16576449 0.88 KDR (0.59) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL27805303 0.86 KDR (0.47) ALDH1A1KDRCHEK1FGFR1CDK4
SCHEMBL4144767 0.85 KIT (0.48) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL4144602 0.83 KDR (0.43) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL4155522 0.81 NR1H2 (0.45) KDRCHEK1FGFR1
SCHEMBL2448984 0.80 KDR (0.45) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL12907469 0.78 JAK2 (0.53) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL27805305 0.78 CHEK1 (0.43) ALDH1A1KDRCHEK1FGFR1HSD17B10
SCHEMBL4134957 0.78 KDR (0.40) KDRCHEK1FGFR1CDK4CCND1
SCHEMBL29919843 0.77 KDM4E (0.50) ALDH1A1HSD17B10HTTLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143422-A1 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC. (US) 2009-06-04 US claimed
EP-2039685-A2 Heterobicyclic compounds as P38 inhibitors Array Biopharma, Inc. (US) 2009-03-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143422-A1 P38 INHIBITORS AND METHODS OF USE THEREOF MAPKAPK2, MAPK1, MAPK8 ALDH1A1 2076/4885KDR 2788/4885CHEK1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.